This investigation compound was 1st described by Hoffman-La Roche in 2009. It’s one of various benzodiazepines in the imidazobenzodiazepine subgroup believed to supply nootropic Rewards. Diazepam is frequently considered the benchmark for assessing the potency of other benzodiazepines. Pote